Danazol for Treatment of Cytopenias in Patients With Cirrhosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Cirrhosis, LiverCytopenia
Interventions
DRUG

Danazol Pill

"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."

Trial Locations (1)

90033

RECRUITING

Keck Hosital of USC, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER